Alcohol Use Disorder
AUD is characterised by compulsive, harmful drinking, and is associated with significant health risks, including chronic diseases, mental health conditions and accidents, injuries and violence.
Rates of AUD have risen since Covid, affecting approximately 29 million adults in the US, and a further 11 million in key European markets. Yet just 10% of sufferers seek treatment. Of those, up to 75% relapse within 12 months. This combination of high prevalence and low treatment success rates poses a significant public health concern – and an urgent unmet need.
29 million sufferers in the US
11 million in key European markets
75% of patients relapse within 12 months
An urgent, unmet need
There’s a key opportunity for effective treatments. But fresh hope needs a fresh approach. Solvonis offers a breakthrough solution to AUD and further potential in other substance use conditions, through novel therapeutics that help us address the roots of these complex conditions.
With the potential to expand into other areas of mental health in time, we believe we can give hundreds of millions of patients the confidence to seek help, recover and live healthier, happier lives.